CONMED (CNMD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [6] - For the full year, sales reached $1.375 billion, representing a year-over-year growth of 5.2% as reported and 5.1% in constant currency [6] - Adjusted earnings per share (EPS) for Q4 were $1.43, growing 6.7%, while full-year adjusted EPS was $4.59, an increase of 10.1% [6][23] Business Line Data and Key Metrics Changes - Orthopedic sales increased by 12.1% in Q4 and 5.5% for the full year on a constant currency basis [6] - General surgery sales grew by 3.8% in Q4 and 4.7% for the full year in constant currency [6] - U.S. orthopedic sales grew 6.6%, while international orthopedic sales increased 15.7% in Q4 [17] - U.S. general surgery sales declined by 0.4%, while international sales increased by 14.8% in Q4 [18] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased by 1.4% [17] - The decline in U.S. general surgery was attributed to a focus on exiting non-core product lines [18] Company Strategy and Development Direction - The company plans to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair [7] - A strategic decision was made to exit the gastroenterology product lines to concentrate resources on stronger growth drivers, expected to improve long-term growth margins by approximately 80 basis points [7][8] - The company aims to stabilize and scale its supply chain while building a high-performance, agile supply chain to support sustained innovation [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving above-market growth by focusing on core strengths and normalizing supply in sports medicine [15] - The company anticipates continued growth in its AirSeal and BioBrace platforms, with AirSeal expected to deliver high single-digit to low double-digit growth rates [10][13] - The CFO transition is underway, with a focus on maintaining continuity and shareholder value [16] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization, equating to approximately $0.07 EPS in 2026 [15] - Adjusted gross margin for Q4 was 56.6%, down 100 basis points from the prior year, while full-year adjusted gross margin was 56.4%, an increase of 10 basis points [21] Q&A Session Summary Question: Can you discuss the cadence for the rest of the year and any selling day differences? - Management confirmed no selling day differences and indicated that the rest of the year should follow the typical med tech calendar [32] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong team player [34] Question: Can you clarify the organic revenue numbers presented at the healthcare conference versus today? - The difference is due to final numbers rolling out, with the current guidance being more precise [37] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales beat was attributed to committed sales professionals, improving supply chain, and new product approvals, while general surgery faced challenges due to portfolio management [40][42] Question: How will the GI business be reported going forward? - The GI business will be reported separately, reflecting its exit from the main revenue figures [54] Question: What are the growth trends for AirSeal internationally? - AirSeal continues to perform within the expected growth range, with opportunities in both robotic and laparoscopic procedures [68]